🚀 VC round data is live in beta, check it out!
Nika Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nika Pharmaceuticals and similar public comparables like Pharmicell, BridgeBio Oncology, Relmada Therapeutics, Allogene Therapeutics and more.
Nika Pharmaceuticals Overview
About Nika Pharmaceuticals
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution of the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.
Founded
2000
HQ
Employees
0
Website
Sectors
Financials (FY)
EV
$765M
Nika Pharmaceuticals Financials
Nika Pharmaceuticals reported last fiscal year revenue of — and negative EBITDA of ($76K).
In the same fiscal year, Nika Pharmaceuticals generated ($76K) in EBITDA losses and had net loss of ($76K).
Nika Pharmaceuticals P&L
In the most recent fiscal year, Nika Pharmaceuticals reported revenue of — and EBITDA of ($76K).
Nika Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($76K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($76K) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nika Pharmaceuticals Stock Performance
Nika Pharmaceuticals has current market cap of $765M, and enterprise value of $765M.
Market Cap Evolution
Nika Pharmaceuticals' stock price is $0.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $765M | $765M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNika Pharmaceuticals Valuation Multiples
Nika Pharmaceuticals trades at (10006.8x) EV/EBITDA.
Nika Pharmaceuticals Financial Valuation Multiples
As of April 20, 2026, Nika Pharmaceuticals has market cap of $765M and EV of $765M.
Equity research analysts estimate Nika Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nika Pharmaceuticals has a P/E ratio of (10006.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $765M | XXX | $765M | XXX | XXX | XXX |
| EV (current) | $765M | XXX | $765M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10006.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (10006.8x) | XXX | XXX | XXX |
| P/E | — | XXX | (10006.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9597.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nika Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nika Pharmaceuticals Margins & Growth Rates
Nika Pharmaceuticals' revenue in the last fiscal year grew by —.
Nika Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (20%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nika Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nika Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmicell | XXX | XXX | XXX | XXX | XXX | XXX |
| BridgeBio Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Relmada Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Allogene Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Gyre Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nika Pharmaceuticals M&A Activity
Nika Pharmaceuticals acquired XXX companies to date.
Last acquisition by Nika Pharmaceuticals was on XXXXXXXX, XXXXX. Nika Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nika Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNika Pharmaceuticals Investment Activity
Nika Pharmaceuticals invested in XXX companies to date.
Nika Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Nika Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nika Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nika Pharmaceuticals
| When was Nika Pharmaceuticals founded? | Nika Pharmaceuticals was founded in 2000. |
| Where is Nika Pharmaceuticals headquartered? | Nika Pharmaceuticals is headquartered in United States. |
| How many employees does Nika Pharmaceuticals have? | As of today, Nika Pharmaceuticals has over 0 employees. |
| Is Nika Pharmaceuticals publicly listed? | Yes, Nika Pharmaceuticals is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Nika Pharmaceuticals? | Nika Pharmaceuticals trades under NIKA ticker. |
| When did Nika Pharmaceuticals go public? | Nika Pharmaceuticals went public in 2024. |
| Who are competitors of Nika Pharmaceuticals? | Nika Pharmaceuticals main competitors are Pharmicell, BridgeBio Oncology, Relmada Therapeutics, Allogene Therapeutics. |
| What is the current market cap of Nika Pharmaceuticals? | Nika Pharmaceuticals' current market cap is $765M. |
| Is Nika Pharmaceuticals profitable? | No, Nika Pharmaceuticals is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.